trop2spotlight.com Open in urlscan Pro
20.50.139.246  Public Scan

Form analysis
0 forms found in the DOM

Text Content

X
The Daiichi Sankyo website uses cookies to offer a better browsing experience.
There is no case that individuals will be specified or personal information will
be collected by cookies. Read More>

SKIP TO MAIN CONTENT

For US Healthcare Professionals




For US Healthcare Professionals


 * Home
 * Unmet needs
 * TROP2 expression
 * Expert insights

Stay Updated

×
BrowserNotSupport


SHINE A LIGHT
ON THEIR SHARED CONNECTION
IN MNSCLC

Expressed in >90% of NSCLC tumors, is TROP2 a way out of the dark?1

learn about trop2
SCROLL


LIMITED 2L+ OPTIONS LEAVE TOO MANY PATIENTS IN THE DARK2

Additional therapies are needed for patients with metastatic non-small cell lung
cancer (mNSCLC), following progression on front-line treatment.2,3

Uncover more in mNSCLC

Uncover more in mNSCLC

*Enrolled in this retrospective study were a total of 331 NSCLC patients (228
adenocarcinoma cases and 103 squamous cell carcinoma cases); TROP2 was measured
using an IHC-based assay.


BROAD EXPRESSION OF TROP2

TROP2 is one of several cell surface proteins expressed in NSCLC.4-8

TROP2 is one of several cell surface proteins expressed in NSCLC.4-8



More about Cell Surface Proteins

*Enrolled in this retrospective study were a total of 331 NSCLC patients (228
adenocarcinoma cases and 103 squamous cell carcinoma cases); TROP2 was measured
using an IHC-based assay.

More about Cell Surface Proteins
go to expert


HEAR FROM THE
EXPERTS

Hear from the experts

Brian Puckett, PharmD, MD moderates a discussion between Balazs Halmos, MD, MS
and Lyudmila Bazhenova, MD about cell surface proteins and mNSCLC.

WATCH NOW



THE POTENTIAL TO REACH MORE PATIENTS

Sign up today to receive updates on the latest innovative approaches in lung
cancer.

SIGN UP
Download and share the facts

2L+=second-line and later; HER3=human epidermal growth factor receptor 3;
c-MET=mesenchymal-epithelial transition factor; ITGB6=integrin beta 6;
TROP2=trophoblast cell surface antigen 2.

References: 1. Mito R, Matsubara E, Komohara Y, et al. Pathol Int.
2020;70(5):287-294. 2. Santos ES. Expert Rev Anticancer Ther.
2020;20(3):221-228. 3. Ahmed Y, Berenguer-Pina JJ, Mahgoub T. Oncology.
2021;99(10):673-680. 4. Li Z, Jiang X, Zhang W. Biochem Biophys Res Commun.
2016;470(1):197-204. 5. Blumenthal RD, Leon E, Hansen HJ, et al. BMC Cancer.
2007;7:2. 6. Deng H, Shi H, Chen L, et al. Cancer Cell Int. 2019;19:106. 7.
Altan M, Pelekanou V, Schalper KA, et al. Clin Cancer Res.
2017;23(17):5202-5209. 8. Castellanos JR, Purvis IJ, Labak CM, et al. Am J Clin
Exp Immunol. 2017;6(4):66-75.

 * Sitemap
 * Contact Us
 * Terms and conditions
 * Privacy Policy

© 2024 Daiichi Sankyo, Inc. and AstraZeneca.

PP-US-1062-0315 06/24


You are now leaving TROP2Spotlight.com

Would you like to continue?

NO
YES